[ACN Newswire] – By Jake KingShares of ArQule (NASDAQ:ARQL) are up 8% on news that the FDA has agreed to a Special Protocol Assessment for the company’s planned Phase III tivantinib trial. ArQule is designing a study of … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingShares of ArQule (NASDAQ:ARQL) are being crushed in early trading on Tuesday following an announcement that ArQule and partner Daiichi Sankyo (OTC:DSNKY) will be discontinuing a Phase III non … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Contact: William B. Boni VP, Investor Relations/Corp. Communications ArQule, Inc. (781) 994-0300 www.ArQule.com Tara Camp Daiichi Sankyo, Inc. (US) (973) 944-2393 (908) 577-4531 Michaela Paudler-Debus, … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboard […]
